1 December: World AIDS Day

The 1st of December marks World Aids Day which creates awareness of the millions living with HIV & AIDS.

To recognize this day, the Pharma Intelligence Report Store is offering 20% off select HIV/AIDS reports covering prescribed trends, key marketed therapies, impact of generic launches, and more.

Visit the Report Store today and use aids20 at checkout to take advantage of this special offer.

Related Reports

The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages.

A German key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.

Enquire

Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson & Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.

A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.